1. India Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Deccan Health Care Ltd

Deccan Health Care Ltd

DECCAN.BO
Deccan Health Care LtdIN flagBombay Stock Exchange
13.43
INR
-0.27
- -
332.38MMarket Cap
Deccan Health Care Ltd
DECCAN.BO
(Bombay Stock Exchange)

Recent

price

13.43

P/E

ratio

- -

div

yld

- -

ROIC.AI

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
10.28
18.67
29.06
31.43
26.88
21.49
21.11
35.3
32.1
34.98
- -
33.87
Revenue per Share
2.25
6.07
10.26
10.29
6.42
0.25
0.21
0.24
0.8
0.54
- -
1.03
Basic EPS, GAAP
1.94
0.56
5.94
-1.29
-0.49
0.04
-0.44
-5.3
-6.74
-3.06
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-18.13
-10.47
4.99
8.81
14.32
14.56
14.79
18.92
15.56
15.46
- -
10.24
Book Value per Share
5.35
14.09
35.47
46.99
48.51
48.72
48.94
63.94
52.07
49.57
- -
45.59
Tangible Book Value per Share
16
16
13
14
16
16
16
13
19
21
- -
24
Basic Weighted Avg Shares
162
293
378
442
422
338
332
450
597
751
819
819
Sales/Revenue/Turnover
32.16
39.59
33.77
35.07
24.28
4.52
12.53
1.33
3.83
2.26
4.42
4.42
Operating Margin (%)
12
12
13
13
14
15
15
14
15
15
15
15
Depreciation Expense
35
95
134
145
101
4
3
3
15
12
25
25
Net Income, GAAP
0.19
- -
- -
0.59
0.44
24.89
40.53
30.38
32.58
28.92
23.83
23.83
Effective Tax Rate (%)
21.92
32.51
35.32
32.73
23.88
1.15
0.97
0.68
2.5
1.54
3.04
3.04
Profit Margin (%)
71
158
253
435
523
537
574
640
807
905
957
957
Working Capital
139
108
85
9
9
7
9
14
17
9
27
27
LT Debt
84
221
462
661
762
766
769
816
969
1,064
1,103
1,103
Total Equity
- -
- -
- -
24.35
13.93
1.46
3.14
0.51
1.67
1.16
2.45
2.45
Return on Invested Capital (%)
- -
- -
- -
99.09
54.38
1.85
1.59
1.46
5.41
3.72
8.78
8.78
Return on Capital (%)
- -
- -
- -
153.15
57.8
1.72
1.4
1.29
5.62
3.73
8.59
8.59
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
5
- -
13
LT Borrowings
14
- -
27
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
25
- -
25
Market Capitalization
451
361
166

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
1,204
- -
1,297
Cash, Cash Equivalents & STI
19
- -
25
Accounts Receivable, Net
146
- -
170
Inventories
459
- -
470
Total Current Liabilities
261
- -
340
Payables & Accruals
- -
- -
- -
ST Debt
5
- -
13
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
36.97%
7.73%
3.64%
Free Cash Flow
11.4%
-61.03%
-5.8%
Net Income, GAAP
54.88%
91.51%
114.69%
Sales/Revenue/Turnover
20.43%
20.28%
9.12%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
112
172
153
160
597
2025
151
188
204
207
751
2026
221
214
174
210
819

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.18
0.32
0.29
- -
0.8
2025
0.18
0.26
0.07
0.05
0.54
2026
0.1
0.37
0.41
0.14
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Redcare Pharmacy N.V. (RDC.DE)
Swedish Orphan Biovitrum AB (SOBI.ST)
Probi AB (publ) (0GZB.L)
Chugai Pharmaceutical Co., Ltd. (CHGCF)
Hanall Biopharma Co., Ltd. (009420.KS)
TG Therapeutics, Inc. (0VGI.L)
Business
Deccan Health Care Limited (DECCAN.BO) manufactures and markets nutraceuticals and wellness products focused on fast-moving consumer healthcare (FMCH), including food pills and meals addressing 52 consumer wellness goals to prevent over 200 diseases, disorders, and disabilities from micronutritional deficiencies; its portfolio encompasses over 1,500 market-ready products across categories such as immune support, cardiovascular health, digestive aids, personal care, weight management, vitamins and minerals, probiotics, proteins and peptides, omega fatty acids, and general health solutions in forms including capsules, tablets, soft gels, powders, liquids, and gummies; key brands and offerings under Be Young include Stay Young Food Pill, Stay Young Protein Shake, Stay Young Slim Meal, OmegaMax TOTAL, OxyFlax NANO, Lignofiax, Neurovit MC, CardoDecc, Ostohealth, Orthomega, O3D3, ReactiveGo, Maxicare, ProstaDecc, and ayurvedic products like Herbs Cough Syrup, Nutrient Tulsi Honey, and Omega 3 supplements, sold primarily through e-commerce platforms such as www.beyoungstore.com. Founded in 1996 and headquartered in Hyderabad, Telangana, India, the company operates globally with presence in regions including Africa (Botswana, Kenya, Tanzania, Mauritius, Ethiopia, Mozambique, South Africa), Asia and Middle East (India, Nepal, Kazakhstan, Yemen, Philippines), Europe (United Kingdom, Russia, Ukraine), North America (United States), and Australasia. In recent developments, Deccan Health Care converted multiple tranches of convertible warrants into equity shares in 2024 and 2025, including allotments to Focal Ventures Private Limited and Krishna Ventures in April and December 2024; the company appointed Mohak Gupta as Additional Executive Director and extended its POSHAN MAITRI project under POSHAN Abhiyaan with the Himachal Pradesh government in September 2025; it reported net profit growth of 71.70% to Rs 0.91 crore for the quarter ended September 2025, with sales up 13.71% to Rs 21.40 crore, alongside consolidated financial results for March 2025 showing revenue of Rs 75.06 crore and profit of Rs 1.16 crore; promoter holding decreased to 18.4% amid low but stable debt levels and a strong balance sheet.